Etude Des Facteurs Prédictifs De L'apparition Et De L'évolution De La Maladie De Parkinson

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Observational, prospective, monocentric study to assess clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients and rate of progression compared to healthy controls (HC) and subjects at risk to develop PD. The primary objective of this study is to identify clinical, imaging and biologic markers of PD onset and progression for use in clinical trials of disease-modifying therapies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• All subjects: Male or female age 18 years and older, MMSE score \> 26, negative pregnancy test in potentially child-bearing women (contraindication to SPECT with DatScan).

• Idiopathic Parkinson disease subjects: diagnosis confirmed according to UK Parkinson's Disease Society Brain Bank criteria (UKPDSBB); disease duration less than 3 years.

• Genetic Parkinson disease subjects: parkinson diagnosis confirmed and mutation in parkin, LRRK2, SNCA or GBA genes.

• Prodromal subjects: subjects with identified relative with PD genetically confirmed or subjects with diagnosis of idiopathic Rem sleep Behavior Disorder (iRBD); neurological examination normal (no signs of parkinsonism).

• Healthy subjects: neurological examination normal

Locations
Other Locations
France
Hôpital Pitié-Salpêtrière
RECRUITING
Paris
Contact Information
Primary
Marie VIDAILHET, PhD
marie.vidailhet@psl.aphp.fr
Time Frame
Start Date: 2014-11-06
Estimated Completion Date: 2029-11-06
Participants
Target number of participants: 360
Treatments
Patients with an idiopathic Parkinson Disease,
Patients with recent onset of Parkinson Disease: N=200
Subjects at risk of PD
Subjects at risk to develop Parkinson Disease:~* subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~* subjects related to a patient with genetically confirmed Parkinson Disease: N=30
Controls
Healthy controls: N=50
Patients with Parkinson Disease with genetic mutation
Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
Related Therapeutic Areas
Sponsors
Leads: Institut National de la Santé Et de la Recherche Médicale, France
Collaborators: IHU-A-ICM, Paris, France

This content was sourced from clinicaltrials.gov